Mealey's (November 4, 2022, 3:31 PM EDT) -- WASHINGTON, D.C. — A petition for writ of certiorari by Amgen Inc., whose patents associated with the monoclonal antibody drug “Repatha” were declared invalid by a Delaware federal judge for lack of enablement on remand from the Federal Circuit U.S. Court of Appeals, was granted Nov. 4 by the U.S. Supreme Court....